Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: A double blind, randomized cross-over trial

Movement Disorders

Volumn 22, Issue 16, 2007, Pages 2359-2364

  Vitale, Carmine ^a,b   Marconi, Stefano ^c   Di Maio, Luigi ^a   De Michele, Giuseppe ^a   Longo, Katia ^a   Bonavita, Vincenzo ^a,b   Barone, Paolo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Istituto di Diagnosi e Cura Hermitage Capodimonte   (Italy)

^c CHIESI FARMACEUTICI S P A   (Italy)

Author keywords

Apomorphine hydrochloride; Continuous infusion; Huntington's disease

Indexed keywords

APOFIN; APOMORPHINE; DOMPERIDONE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIAGNOSTIC PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DYSKINESIA; FEMALE; HAMILTON SCALE; HUMAN; HUNTINGTON CHOREA; HYPOTENSION; INVOLUNTARY MOVEMENT; MALE; MOOD DISORDER; NAUSEA AND VOMITING; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIPARKINSON AGENTS; APOMORPHINE; CROSS-OVER STUDIES; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HUNTINGTON DISEASE; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MOOD DISORDERS; MOVEMENT; MOVEMENT DISORDERS; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES;

EID: 38549166606     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21718     Document Type: Article

References (34)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-983
2. Gusella JF, MacDonald ME, Ambrose CM, Duyao MP. Molecular genetics of Huntington's disease. Arch Neurol 1993;50:385-389.
3. Jankovic J, Beach J. Long term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48:358-362.
4. Girotti F, Carella F, Scigliano G, et al. Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease. J Neurol Neurosurg Psychiatry 1984;47:848-852.
5. Barr AN, Fischer JH, Koller WC, Spunt AL, Singhal A. Serum haloperidol concentration and choreiform movements in Huntington's disease. Neurology 1988;38:84-88.
6. Erdemoglu AK, Boratav C. Risperidone in chorea and psychosis of Huntington's disease. Eur J Neurol 2002;9:182-183.
7. Bonelli RM, Niederwieser G, Diez J, Tringer PK. Riluzole and olanzapine in Huntington's disease. Eur J Neurol 2002;9:183-184.
8. Tan BK, Leijnse-Ybena HS, Van den Brand TT. Levodopa in Huntington's chorea. Lancet 1972;1:903.
9. Agnoli A, Ruggieri S, Casacchia M. Restatement and prospectives of ergot alkaloids in clinical neurology and psychiatry. Pharmacology 1978;16:174-188.
10. Frattola L, Albizzati MG, Trabucchi M. Bromocriptine and Huntington's chorea. Arch Neurol 1978;35:60.
11. Frattola L, Albizzati MG, Bassi S, Trabucchi M. Dyskinesia, distonia, and dopaminergic system: effect of apomorphine and ergot alkaloids. In: Corsini GU, Gessa GL, editors. Apomorphine and other dopaminomimetic, Vol 2. Clinical Pharmacology. New York: Raven Press; 1981. p 145-152
12. Trabucchi M. Role of pre- and post-synaptic receptors in the treatment of Huntington's chorea. In: Gardone, editor. Problems on extrapyramidal dysfunction. Milan, Italy: 1976.
13. Trabucchi M, Andreoli VM, Frattola L, Spano PF. Pre- and post-synaptic action of bromocriptine. Its pharmacological effects in schizophrenia and neurological disease. In: Costa E, and Gessa GL, editors. Advances in biochemistry and psychopharmacology. New York: Raven Press; 1977. p 661-665.
14. Caraceni TA, Girotti F, Giovannini P, Pederzoli M, Parati EA. Effects of DA agonists in Huntington disease hyperkinesia. Ital J Neurol Sci 1980;3:155-162.
15. Tolosa ES, Sparber SB. Apomorphine in Huntington's disease: clinical observations and theoretical considerations. Life Sci 1974;15:1371-1380.
16. Corsini GU, Del Zompo M, Manconi S, Cianchetti C, Gessa GL. Sedative, hypnotic and antipsychotic effects of low doses of apomorphine in man. Adv Biochem Psychopharmacol 1977;16:645-648.
17. Corsini GU, Tonali PL, Masala C, Cianchetti C, Mangoni A, Gessa GL. Apomorphine hydrocloride-induced improvement in Huntington's chorea. Arch Neurol 1978;35:27-30.
18. Corsini GU, Del Zompo M, Cianchetti M, Mangoni A, Gessa GL. Therapeutical efficacy of a combination of apomorphine with sulpiride or metoclopramide in parkinsonism. Psychopharmacology 1976;47:169-173.
19. Bentivoglio AR, Albanese A, Granata R, Colosimo C, Tonali P. Apomorphine injections acutely improve chorea in patients with Huntington's disease. Mov Disord 1992;7 (Suppl):180.
20. Folstein SE, Leigh RJ, Parhad IM, Folstein MF. The diagnosis of Huntington's disease. Neurology 1986;36:1279-1283.
21. Folstein MS, Folstein SE, McHugh PR. "Mini Mental State" a practical method for grading the cognitve state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
22. Warner JP, Barron LH, Brock DJ. A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is expanded and unstable on Huntington's disease chromosome. Mol Cell Probes 1993;7:235-239.
23. Huntington Study Group. Unified Huntington's disease rating scale: reliability and consistency. Mov Disord 1996;2:136-142.
24. AIMS. In: Guy W, editor. ECDEU Assessment manual. Rockville (Maryland): US department of Health, Education and Welfare; 1976
25. Simpson GM, Lee JH, Houbok B, Gardos G. A rating scale for tardive dyskinesia. Psychopharmacol 1979;64:171-179.
26. Hamilton MA. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
27. Gancer ST, Woodward WR, Boucher B, Nutt JG. Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol 1989;26:232-238.
28. Meltzer HY. Dopamine autoreceptor stimulation: clinical significance. Pharmacol Biochem Behav 1982;17 (Suppl 1):1-10.
29. Tesarova O. Mechanism of thymoleptic drug action studied in the model of apomorphine depression. Activitas Nerv Sup 1968;10:287-288.
30. Tesarova O. Experimental depression caused by apomorphine and phenoharmane. Pharmakopsychiatrie 1972;5:13-19.
31. Tesarova O, Molcan J. A contribution to the problem of experimental depression. Activitas Nerv Sup 1966;8:551-552.
32. Lal S, De La Vega CE. Apomorphine and psychopathology. J Neurol Neurosurg Psychiatr 1975;38:722-726.
33. Maany I, Mendels J, Frazer A, Brunswick D. A study of growth hormone release in depression. Neuropsychobiology 1979;5:282-289.
34. Lal S, De La Vega CE, Garelis E, Sourkes TL. Apomorphine, pimozide, L-Dopa and the probenecid test in Huntington's chorea. Psychiatria Neurologia Neurochirurgia 1973;76:113-117.